Newron details FDA safety concerns behind evenamide hold, says Phase III continues

8 October 2026

Italian neuroscience company Newron Pharmaceuticals (SIX: NWRN; XETRA: NP5) has set out the US Food and Drug Administration's (FDA) reasons for the clinical hold at US sites in its Phase III ENIGMA-TRS 2 trial of evenamide in treatment-resistant schizophrenia (TRS), and said it is preparing a response.

According to Newron, the FDA's written communication cites the known risk that some sodium channel blockers can trigger arrhythmias, which in turn can lead to serious cardiovascular events or seizures. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical